Influenza Virus Vaccine (2025-2026 Flu Season)   4

PRE-SOLICITATION NOTICE: The VA National Acquisition Center intends to issue a Request for Proposal (RFP) 36E79724R0031 for an unrestrictive procurement for the Influenza Virus Vaccine for the Department of Veterans Affairs (VA) to include State Veteran Homes option 2 (SVH2 s), Bureau of Prisons (BOP), Indian Health Service (IHS), and Captain James A. Lovell Federal Health Care Center (FHCC) for the 2025-2026 influenza season. Evaluation and award will be made by solicitation line item for VA, BOP, IHS, and FHCC requirements. Offerors are not required to submit an offer for every line item; however, the offeror must offer the full quantity for each line item offered. Additionally, all offered line items for a single presentation must be offered at the same unit price. Please note that the final offered price must include the Cost Recovery Fee (CRF) and Federal Excise Tax (FET). Orders will be placed by and delivered to VA, SVH2, BOP, and IHS facilities throughout the United States, the Philippines and Puerto Rico. The contractor(s) will be required to deliver the vaccine Free On Board (FOB) Destination to Government facilities within the U.S., Philippines, and Puerto Rico. The first shipment of product ordered must be at least 50% of each individual facility s ordered quantity and must be delivered between August 15, 2025, and September 15, 2025. The second shipment must be for the remaining individual facility s entire ordered quantity and must be delivered between September 16, 2025, and October 15, 2025. FHCC shall receive 100% of the awarded quantities between August 15, 2025, and September 15, 2025. Solicitation number 36E79724R0031 is estimated to be electronically issued in commercial item format in accordance with FAR Part 12 on or about September 18, 2024, with a closing date of October 2, 2024. ESTIMATED ANNUAL REQUIREMENTS BY AGENCY PRESENTATION DESCRIPTION PACKAGE TYPE VA EST ANNUAL USAGE BOP EST ANNUAL USAGE IHS EST ANNUAL USAGE FHCC EST ANNUAL USAGE TOTAL ESTIMATED ANNUAL USAGE 1 Influenza Virus Vaccine: 10 dose multiple dose vial, or 10 - 0.5ml Vials, Quadrivalent; 2025-2026 Influenza season; for persons 6 months, latex free. VIAL (10 doses/vial or box of 10 individual vials) 6,500 2,033 2,676 0 11,209 2 Influenza Virus Vaccine: Pre-filled single dose syringes with plunger and Luer lock needle attachment, Quadrivalent; 2025-2026 Influenza season; for persons 36 months. SYRINGE (Box of 10) 120,000 3,556 29,198 750 153,504 3 Influenza Virus Vaccine: Pre-filled single dose syringe with plunger and Luer lock needle attachment, Quadrivalent or Trivalent; 2025-2026 Influenza season; must be specifically designed for persons 65 years and older as outlined by the CDC. SYRINGE (Box of 10) 120,000 236 11,637 400 132,273 4 Influenza Virus Vaccine: Pre-filled single dose syringe with plunger and Luer lock needle attachment, Quadrivalent; 2025-2026 Influenza season. Must be split virus vaccine (subvirion or purified surface antigen) that has been FDA approved and labeled with indications for administration to children 6 months - 35 months of age (pediatric), preservative free. SYRINGE (Box of 10) 0 0 1,462 0 1,462 Quadrivalent presentation is currently specified. However, this may change if the World Health Organization (WHO) recommends the Trivalent presentation for any of the dose types. If both presentations are recommended by WHO and offered commercially by the offeror/contract awardee, then the Quadrivalent presentation would be required.